PBAC Guidelines (Guidelines for preparing a submission to the Pharmaceutical Benefits Advisory Committee, Version 5.0)
These guidelines explain how to prepare a submission to get a new medicine listed on Australia's Pharmaceutical Benefits Schedule. They outline what clinical and economic evidence is needed and how it should be presented to the Pharmaceutical Benefits Advisory Committee and its Economic Sub-Committee.
At a glance
Use when
Preparing a submission for pharmaceutical reimbursement listing in Australia via the PBAC process.
Avoid when
Conducting independent health technology assessments requiring replicable and transparent modeling standards or when high scientific rigor and external validation are essential.
Inputs
Clinical trial data, cost-effectiveness analyses, budget impact models, quality of life metrics, and comparative efficacy data.
Outputs
Structured submission dossiers for PBAC review, including evidence summaries and economic models supporting reimbursement decisions.
How it works
Version 5.0 of the PBAC Guidelines, published in 2016 by the Australian Department of Health, provides a framework for submitting dossiers to support the listing of pharmaceuticals on the PBS. The document specifies requirements for clinical evidence synthesis, economic modeling standards, and presentation formats for review by the PBAC and ESC. However, a critical commentary suggests that the guidelines do not fully support empirically evaluable, credible, or replicable claims, falling short of 'normal science' standards in terms of transparency and feedback mechanisms for decision-making.
- HTA domains
- Clinical Effectiveness, Costs & Economic Evaluation, Organisational aspects
- Categories
- AppraisalContext & ImplementationCost-effectiveness ModellingReporting Standards & Best Practice
- Assumptions
- Sponsors will generate evidence aligned with PBAC expectations; modeled cost-effectiveness reflects real-world value; submitted data is of sufficient quality and transparency for appraisal.
- Strengths
- Provides a standardized framework for pharmaceutical reimbursement submissions; widely used in the Australian health system; includes guidance on both clinical and economic evidence.
- Limitations
- Lacks requirements for empirically evaluable, replicable, or falsifiable claims; limited transparency in model assumptions; does not support systematic feedback or validation of submitted claims.
- Also known as
- PBAC Submission Guidelines Version 5.0, Guidelines for Preparing Submissions to the PBAC, Australian PBAC Guidelines v5.0
Questions this answers
- › What clinical evidence is required to support a medicine's listing on the PBS?
- › How should economic evaluations be structured for PBAC review?
- › What format should submissions follow for PBAC assessment?
- › What role does the Economic Sub-Committee play in evaluating submissions?
- › How are cost-effectiveness claims assessed within the PBAC framework?
- › What standards are expected for modeling in PBAC submissions?
References & sources
Similar by meaning
Beta record. Based on the original catalogue summary; primary-source enrichment pending.